Rhythm Pharmaceuticals (RYTM) Shares Outstanding (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Shares Outstanding (Entity) for 11 consecutive years, with $68.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 7.8% year-over-year to $68.4 million; the TTM figure through Mar 2026 stood at $68.4 million (up 7.8% YoY), while the FY2025 annual figure was $67.2 million, up 7.72% from the prior year.
• Shares Outstanding (Entity) grew to $68.4 million in Q1 2026 per RYTM's latest filing, from $67.2 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $68.4 million in Q1 2026 and bottomed at $50.4 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $60.1 million across 5 years, with a median of $61.0 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 0.38% — and 2023, when it rose 12.82%.
• Rhythm Pharmaceuticals' Shares Outstanding (Entity) stood at $56.6 million in 2022, then grew by 4.97% to $59.4 million in 2023, then rose by 4.99% to $62.4 million in 2024, then rose by 7.72% to $67.2 million in 2025, then climbed by 1.84% to $68.4 million in 2026.
• Business Quant data shows RYTM's Shares Outstanding (Entity) at $68.4 million in Q1 2026, $67.2 million in Q4 2025, and $66.7 million in Q3 2025.